Ashley Gallagher, Editor

Data indicate that consumption of 7 or more units of alcohol per week is associated with higher iron levels in the brain, which has been linked to Alzheimer and Parkinson diseases.

Data from Roche’s phase 3 HAVEN 6 study show clinically meaningful bleed control, with no new safety signals observed.

Phase 3 study follows recent approval of the drug for the same condition in individuals aged 12 years and older who weight at least 40 kg.

About one-third of participants in the phase 1b cohort of the KRYSTAL-1 study show an intracranial response, according to Mirati Therapeutics.

The investigational PCV is designed to target serotypes responsible for 85% of all invasive cases of the disease in individuals aged 65 and older in the United States.

Investigators argue that much of the language around women who give birth later in life is rooted in ableism and ageism and is out of step with current childbirth trends.

Provepharm filed its application with the agency in September 2021, and, with the new approval, its US affiliate will market the product directly in the United States.

A booster dose of both Omicron-adapted vaccine candidates elicited a substantially higher immune response against Omicron BA.1.

Study results show that there is a link between leaving the television on, night lights, and smart phones and higher disease rates.

After 4 years of treatment with ofatumumab, 78.8% of patients with relapsing forms of multiple sclerosis who continuously received ofatumumab achieved NEDA-3 compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Lenacapavir is an investigational, long-acting HIV-1 capsid inhibitor that is not yet approved by any regulatory authority.

Jazz Pharmaceuticals announced top-line results from the phase 3 RELEASE MSS1 trial, evaluating nabiximols oromucosal spray in individuals with multiple sclerosis.

If approved, the 16-week dosing regimen could offer certain individuals a potentially longer treatment interval and physicians with greater flexibility to individualize treatment.

New data show that after 4 years of treatment, 78.8% of patients who continuously received ofatumumab achieved no evidence of disease activity-3 (NEDA-3) compared to 51.8% of those who switched from teriflunomide to ofatumumab.

Findings from a study highlight the efficacy and safety of bulevirtide for the treatment of chronic hepatitis delta virus.

The study included the BNT162b2 and CoronaVac vaccines, which are the only COVID-19 vaccines authorized for emergency use in Hong Kong.

Investigators also noted that Black, Hispanic, and Asian individuals were less likely than white individuals to undergo timely angiography and had minimal changes overtime.

As part of the submission, the companies have also requested priority review with the FDA for elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.

Clorazepate dipotassium tablets are for the management of anxiety disorders or for the short-term relief of symptoms.

Investigators studied the efficacy and safety of eptinezumab-jjmr in the 100 mg and 300 mg intravenous infusion dosages in individuals with 2 to 4 documented unsuccessful prior preventive treatment failures for migraine in the past 10 years.

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

Clinical evaluation dictates the need for preventive therapy and advice on exercising and participation in competitive sports, according to the European Society of Cardiology.

Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.

Analysis results expand understanding of the impact of the company’s medicines in early stages with the goal or providing patients with durable and robust outcomes from their first treatment.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

But investigators find that individuals who had shingles that spread to the central nervous system had nearly twice the risk of developing mental deterioration, though it is rare.

Treatment identifies patients with ROS1 fusion-positive non-small cell lung cancer or those with NTRK fusion-positive solid tumors for whom treatment with Rozlytrek may be appropriate.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.

Study results showed that a lower proportion of participants treated with LAGEVRIO had an acute care visit compared with those who received the placebo.